Alpha Cognition announces US patent application publication for benzgalantamine in persistent post-concussion symptoms
ACOG•Alpha Cognition announced publication of a U.S. patent application covering benzgalantamine for persistent post-concussion symptoms. The drug remains in preclinical development for cognitive impairment associated with mild traumatic brain injury.
1. Patent application published
Alpha Cognition announced publication of a U.S. patent application covering benzgalantamine for persistent post-concussion symptoms. The application includes preclinical animal findings on functional recovery, neuronal preservation and brain pathology following traumatic brain injury; benzgalantamine remains in preclinical development for cognitive impairment associated with mild traumatic brain injury.




